Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Featured Practice Guidelines
    • Drug-induced liver...

    Drug-induced liver injury: EASL Clinical Practice Guidelines

    Written by Medha Baranwal Baranwal Published On 2019-05-14T19:00:28+05:30  |  Updated On 14 May 2019 7:00 PM IST
    Drug-induced liver injury: EASL Clinical Practice Guidelines

    The European Association for the Study of the Liver (EASL) has released clinical practice guidelines for drug-induced liver injury.


    Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed.


    These Clinical Practice Guidelines, published in the Journal of Hepatology suummarizes the available evidence on risk factors, diagnosis, management and risk minimization strategies for the drug-induced liver injury.


    Diagnosis




    • Classify drug-induced liver injury (DILI) as hepatocellular, cholestatic, or mixed according to the pattern of elevation of liver enzymes based on the first set of lab tests available.

    • When suspected, evaluate drug-induced autoimmune hepatitis (AIH) in detail. This includes causality assessment, serology, genetic tests, and liver biopsy.

    • A multidisciplinary team should make decisions regarding corticosteroid treatment of immune-mediated hepatitis associated with immune checkpoint inhibitors.

    • Consider a diagnosis of drug-induced secondary sclerosing cholangitis in patients with a cholestatic pattern of DILI with slow resolution of liver injury and characteristic changes in the biliary system.

    • Consider drugs such as amiodarone, methotrexate, tamoxifen, and the chemotherapeutic agents 5-fluorouracil and irinotecan as risk factors for fatty liver disease.

    • Withdraw drugs associated with nodular regenerative hyperplasia, as they may be considered risk factors.

    • In patients with suspected DILI, use tests for HCV-RNA and ant-HEV IgM (or HEV-RNA) to exclude acute hepatitis C and/or E.

    • Perform an abdominal ultrasound for all patients suspected of having DILI.

    • Consider liver biopsy in patients suspected of having DILI.

    • HLA genotyping may be used to support the diagnosis of DILI due to specific drugs or distinguish DILI from AIH.


    Prognosis




    • A short administration of cholestyramine may be used to decrease the course of hepatotoxicity induced by very selected drugs, such as leflunomide and terbinafine.

    • Carnitine may be used to improve the course of valproate hepatotoxicity.


    Management of Drug-Induced Acute Liver Failure




    • In case of drug-induced acute liver failure (ALF), consider liver transplantation as a therapeutic option.

    • Adults with idiosyncratic drug-induced ALF should receive NAC early in the course (coma grade I–II).


    For detailed guidelines follow the link: https://doi.org/10.1016/j.jhep.2019.02.014
    chemotherapeutic agentsDiagnosisdrug induceddrug-induced autoimmune hepatitisdrug-induced liver injuryEuropean Association for the Study of the LiverIdiosyncraticirinotecanJournal of Hepatologyleflunomideliver failureliver injurymanagementMethotrexaterisk minimizationTamoxifenTerbinafine
    Source : With inputs from Journal of Hepatology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok